Page last updated: 2024-08-26

cb 10375 and Carcinoma 256, Walker

cb 10375 has been researched along with Carcinoma 256, Walker in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (100.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abel, G; Goddard, PM; Harrap, KR; Judson, IR; Newell, DR; Rutty, CJ	1

Other Studies

1 other study(ies) available for cb 10375 and Carcinoma 256, Walker

Article	Year
Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation. Cancer chemotherapy and pharmacology, 1986, Volume: 17, Issue:3 Topics: Altretamine; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Kinetics; Male; Mice; Mice, Inbred BALB C; Plasmacytoma; Rats; Rats, Inbred Strains; Solubility; Triazines	1986

Article

Year

Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.

Cancer chemotherapy and pharmacology, 1986, Volume: 17, Issue:3

Topics: Altretamine; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Kinetics; Male; Mice; Mice, Inbred BALB C; Plasmacytoma; Rats; Rats, Inbred Strains; Solubility; Triazines

1986